TABLE II. Summary of the antimony intralesional infiltration therapy.

Number of infiltrations (median, IQR)	7 (5-8)
Total volume of Glucantime® infiltrated (median, IQR), mL	27.7 (16.4-46.4)
Total antimony dose infiltrated (median, IQR), mg	2243 (1328-3.758)
Treatment duration - days between the first and the last infiltration (median, IQR), days	43 (28-52)
Time until cure (median, IQR), weeks	7 (6-13)
Interval between infiltrations (mean, SD), days	7.6 ± 2.2
Lost to follow-up, n (%)	0 (0)
Adverse events
Local bacterial infection, n (%)	7 (13.2)
Severe adverse event, n (%)	1 (1.9)
Local irritation (erythema/oedema/itching), n (%)	53 (100)
Local vesicles/bullae, n (%)	2 (3.7)
Outcomes
Cured patients at the 45-day visit, n (rate, 95%CI)	32 (60%, 7-72%)
Cured patients at three months, n (%)	46 (87%, 75-94%
Cured patients at six months, n (%)	46 (87%, 75-94%)
Relapse at six months	1/46 (2.2)

IQR: 25-75% interquartile range; SD: standard deviation; 95% CI: 95% confidence interval.